Revertant Mosaicism in Genodermatoses: Natural Gene Therapy Right before Your Eyes

• Published in: Biomedicines Vol. 10; no. 9; p. 2118
• Main Authors: van den Akker, Peter C, Bolling, Maria C, Pasmooij, Anna M. G
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29.08.2022; MDPI
• Subjects: Care and treatment; Collagen; Congenital diseases; Epidermolysis bullosa; Gene therapy; Genes; Genodermatosis; Genotype & phenotype; ichthyosis; Junctional epidermolysis bullosa; Mosaicism; Mutation; natural gene therapy; Patients; Phenotypes; Proteins; revertant mosaicism; Review; Skin; Skin diseases; Therapeutics, Experimental; Netherlands
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10092118

Revertant mosaicism (RM) is the intriguing phenomenon in which nature itself has successfully done what medical science is so eagerly trying to achieve: correcting the effect of disease-causing germline variants and thereby reversing the disease phenotype back to normal. RM was molecularly confirmed for the first time in a genodermatosis in 1997, the genetic skin condition junctional epidermolysis bullosa (EB). At that time, RM was considered an extraordinary phenomenon. However, several important discoveries have changed this conception in the past few decades. First, RM has now been identified in all major subtypes of EB. Second, RM has also been identified in many other genodermatoses. Third, a theoretical mathematical exercise concluded that reverse mutations should be expected in all patients with a recessive subtype of EB or any other genodermatosis. This has shifted the paradigm from RM being an extraordinary phenomenon to it being something that every physician working in the field of genodermatoses should be looking for in every patient. It has also raised hope for new treatment options in patients with genodermatoses. In this review, we summarize the current knowledge on RM and discuss the perspectives of RM for the future treatment of patients with genodermatoses.